Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://sachinaqwg444089.dsiblogger.com/75975854/retatrutide-australia-a-new-hope-for-obesity-treatment